The UK’s leading pharmaceutical industry body has found AstraZeneca in breach of its code of practice over the marketing of Symbicort, the company’s asthma and chronic obstructive pulmonary disease (COPD) inhaler. The ruling by the Prescription Medicines Code of Practice Authority (PMCPA), announced on Wednesday, marks a significant rebuke for the global drugmaker, highlighting concerns over promotional practices and adherence to regulatory standards in the competitive respiratory drug market.
UK Industry Regulator Rules AstraZeneca Violated Marketing Code Over Symbicort Promotion
The UK’s leading pharmaceutical watchdog has concluded that AstraZeneca breached the established marketing code concerning its promotion practices for Symbicort, an asthma and COPD inhaler. The regulator highlighted several instances where AstraZeneca’s promotional activities were found to be misleading, emphasizing product benefits without adequately balancing the potential risks associated…
—-
Author : Samuel Brown
Publish date : 2025-10-24 20:26:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
